Sabizabulin

DRUG2 trials

Sponsors

Veru Inc.

Conditions

Metastatic Breast CancerMetastatic Triple Negative Breast Cancer

Phase 2

P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .

WithdrawnNCT05008510

Veru Inc.Metastatic Triple Negative Breast Cancer

Start: 2021-12-30End: 2023-06-30Updated: 2022-02-08

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

WithdrawnNCT05079360

Veru Inc.Metastatic Breast Cancer

Start: 2023-03-15End: 2024-05-26Updated: 2023-03-24